Chronic Low Back Pain – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Chronic low back pain (cLBP) is a widespread health issue with significant societal ramifications. Chronic back pain is defined as pain that lasts for at least 12 weeks after an initial injury or underlying cause of acute low back pain has been treated. At one year, approximately 20% of people who experience acute low back pain develop chronic low back pain with persistent symptoms. Even if pain persists, this does not always imply a severe underlying cause that can be easily identified and treated. The treatment successfully relieves chronic low back pain in some cases, but pain persists in others despite medical and surgical treatment. Patients into one of several categories: (1) nonspecific low back pain; (2) back pain associated with a radiculopathy or spinal stenosis; (3) back pain referred from a nonspinal source; or (4) back pain associated with another specific spinal cause. For patients with back pain associated with radiculopathy, magnetic resonance imaging or computed tomography, spinal stenosis, or another specific spinal cause may establish the diagnosis and guide management.

The prevalence of chronic low back pain ranges from 4.5% to 12.5% of the population aged 20 to 60 years in the USA.

 

The competitive landscape of Chronic Low Back Pain includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Chronic Low Back Pain across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chronic Low Back Pain Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, Product Event, Country specific Forecast Model, Market uptake, and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Chronic Low Back Pain – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          Bupivacaine TTS           Pfizer    Phase 2

2          AB001 patch     Frontier Biotechnologies Inc.      Phase 2

3          Flurbiprofen Tape          Teikoku Pharma USA, Inc.         Phase 2

4          LY3526318       Eli Lilly and Company    Phase 2

5          Buprenorphine  Braeburn Pharmaceuticals         Phase 3

6          CordSTEM-DD  CHABiotech CO., Ltd     Phase 2

7          Oxycodone DETERx      Collegium Pharmaceutical, Inc.  Phase 3

8          COV155           Mallinckrodt      Phase 3

9          GRT6005          Tris Pharma, Inc.           Phase 2

10        Rexlemestrocel-L          Mesoblast, Ltd. Phase 3

Continued
 

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more